1. Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity.
- Author
-
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, and Richer JK
- Subjects
- Humans, Female, Cell Line, Tumor, Tryptophan Oxygenase metabolism, Tryptophan Oxygenase antagonists & inhibitors, Tryptophan Oxygenase genetics, Tryptophan metabolism, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms drug therapy, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Indoleamine-Pyrrole 2,3,-Dioxygenase antagonists & inhibitors, Neoplasm Invasiveness
- Abstract
Significance: TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF